BioCentury
BioCentury
DATA GRAPHICS | Product Development

The TREM2 pipeline: Date Byte

It’s early days for the target, but the therapies directed at the innate immune receptor has begun to reflect its potential

By Danielle GOlovin, Staff Writer
September 28, 2021 9:09 PM UTC
Updated on Oct 1, 2021 at 5:15 PM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Alector Inc.

AbbVie Inc.

Denali Therapeutics Inc.

Takeda Pharmaceutical Co. Ltd.

Ionis Pharmaceuticals Inc.

Pionyr Immunotherapeutics Inc.

Abcam plc

BCIQ Target Profiles

Triggering receptor expressed on myeloid cells 2 (TREM2)

BCIQ Company Profiles

Alector Inc.

AbbVie Inc.

Denali Therapeutics Inc.

Takeda Pharmaceutical Co. Ltd.

Ionis Pharmaceuticals Inc.

Pionyr Immunotherapeutics Inc.

Abcam plc

BCIQ Target Profiles

Triggering receptor expressed on myeloid cells 2 (TREM2)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS